EC Green Lights Exelixis’ Cotellic for Metastatic Melanoma

The European Commission has approved Exelixis’ Cotellic for use in combination with vemurafenib for treatment of adults with metastatic melanoma with a BRAF V600 mutation.

The combination is approved by the FDA for the treatment of patients with BRAF V600E or V600K mutation-positive metastatic melanoma. Further country approvals are anticipated in 2016, the company says.